Human cell programming company bit.bio closes $25M Series D

Human cell programming company bit.bio has secured $25 million in Series D funding to expand its portfolio of human cell models and increase access to its technology for pharmaceutical companies, biotechnology businesses and research organisations. The investment follows the company's Series C round earlier this year and includes participation from existing investor M&G Investments and Dr Jonathan Milner, founder and former CEO of Abcam.As drug discovery methods evolve, researchers increasingly…